Effect of vehicles on topical delivery of 5-fluorouracil (5FU) by 1-acyl-5FU prodrugs

International Journal of Pharmaceutics

Volumn 154, Issue 1, 1997, Pages 39-48

  Patrick, Ana I ^a,b   Beall, Howard D ^a,c   Gilroy, Patricia ^a   Sloan, Kenneth B ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

1 Alkylcarbonyl 5 FU; 5 Fluorouracil (5 FU) prodrugs; Isopropyl myristate; Skin damage; Transdermal delivery; Triglycerides

Indexed keywords

1 ACETYL 5 FLUOROURACIL; 1 DECANOYL 5 FLUOROURACIL; 1 HEXANOYL 5 FLUOROURACIL; DRUG VEHICLE; FLUOROURACIL; FLUOROURACIL DERIVATIVE; MIGLYOL; MYRISTIC ACID ISOPROPYL ESTER; PRODRUG; PROPYLENE GLYCOL; THEOPHYLLINE; TRIACETIN; TRIBUTYRIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DIFFUSION; DRUG SOLUBILITY; DRUG STABILITY; FEMALE; LIPOPHILICITY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SKIN DEFECT; SKIN PENETRATION; SUSPENSION; TRANSDERMAL DRUG ADMINISTRATION;

EID: 0030837113     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(97)00108-7     Document Type: Article

References (24)

1. Beall, H.D., Prankerd, R.J., Todaro, L.J., Sloan, K.B., 1993. Structure of 3-acetyl-5-fluorouracil (5-FU): Implication for its rearrangements during hydrolysis and upon heating. Pharm. Res. 10, 905-912.
2. Beall, H.D., 1991. Bioreversible Derivatives of 5-Fluorouracil (5-FU): Improving Dermal and Transdermal Delivery with Prodrugs, Ph.D. dissertation, University of Florida, Gainesville, Dec. 1991.
3. Beall, H.D., Prankerd, R.J., Sloan, K.B., 1994. Transdermal delivery of 5-fluorouracil (5-FU) through hairless mouse skin by 1-alkyloxycarbonyl-5-FU prodrugs: Physicochemical characterization of prodrugs and correlation with transdermal delivery. Int. J. Pharm. 111, 223-233.
4. Beall, H.D., Prankerd, R.J., Sloan, K.B., 1996. 1-Alkylcarbonyl-5-fluorouracil prodrugs: Synthesis, thermal and hydrolytic stability. Drug. Dev. Ind. Pharm. 22, 85-90.
5. Beall, H.D., Sloan, K.B., 1996. Transdermal delivery of 5-fluorouracil (5-FU) by 1-alkylcarbonyl-5-FU prodrug. Int. J. Pharm. 129, 203-210.
6. Dillaha, C.J., Jansen, G.T., Honeycutt, W.M., Holt, C.A., 1965. Further studies with topical 5-fluorouracil. Arch. Dermatol. 92, 410-417.
7. Epstein, E., 1985. Fluorouracil paste treatment of thin basal cell carcinomas. Arch. Dermatol. 121, 207-213.
8. Goette, D.K., 1981. Topical chemotherapy with 5-fluorouracil. J. Am. Acad. Dermatol. 4, 633-649.
9. Koch, S.A.M., Sloan, K.B., 1987. N-Mannich base derivatives of 5-fluorocytosine: A prodrug approach to improve topical delivery. Int. J. Pharm. 35, 243-252.
10. Martin, A., Wu, P.L., Velasquez, T., 1985. Extended Hildebrand solubility approach: sulfonamides in binary and ternary solvent. J. Pharm. Sci. 74, 277-282.
11. Ozaki, S., Ike, Y., Mizuno, H., Ishikawa, K., Mori, H., 1977. 5-Fluorouracil derivatives. 1. The synthesis of 1-carbamoyl-5-fluorouracils. Bull. Chem. Soc. (Japan) 50, 2406-2412.
12. Pinedo, H.M., Peters, G.R.J., 1988. Fluorouracil biochemistry and pharmacology. J. Clin. Oncol. 6, 1653-1664.
13. Robinson, T.A., Kligman, A.M., 1975. Treatment of solar keratoses of the extremities with retinoic acid and 5-fluorouracil. Br. J. Dermatol. 92, 703-706.
14. Sasaki, H., Takahashi, T., Mori, Y., Nakamura, J., Shibasaki, J., 1990. Transdermal delivery of 5-fluorouracil and its alkylcarbamoyl derivatives. Int. J. Pharm. 60, 1-9.
15. Sloan, K.B., Koch, S.A.M., Siver, K.G., Flowers, F.P., 1986. The use of solubility parameters of drug and vehicles to predict flux. J. Invest. Dermatol. 87, 244-252.
16. Sloan, K.B., Beall, H.D., Weimar, W.R., Villanueva, R., 1991. The effect of receptor phase composition on the permeability of hairless mouse skin in diffusion cell experiments. Int. J. Pharm. 73, 97-104.
17. Sloan, K.B., 1992. Functional group considerations in the development of prodrug approaches to solving topical delivery problems. In: Sloan, K.B. (Ed.), Topical and Ocular Drug Delivery. Marcel Dekker, New York, pp. 17-116.
18. Sloan, K.B., Beall, H.D., 1993. The prodrug option: Increasing topical delivery. Cosmet. Toiletries 108 (April), 85-92.
19. Sloan, K.B., Getz, J.J., Beall, H.D., Prankerd, R.J., 1993. Transdermal delivery of 5-fluorouracil (5-FU) through hairless mouse skin by 1-alkylaminocarbonyl-5-FU prodrugs. Physicochemical characterization of prodrugs and correlations with transdermal delivery. Int. J. Pharm. 93, 27-36.
20. Tsuji, T., Sugai, T., 1972. Topically administered fluorouracil in psoriasis. Arch. Dermatol. 105, 208-212.
21. Van Scott, E.J., Reinertson, R.P., 1959. Morphologic and physiologic effects of chemotherapeutic agents in psoriasis. J. Invest. Dermatol. 33, 357-369.
22. Vaughan, C.D., 1988. Solubility effects in product, package, penetration and preservation. Cosmet. Toiletries 103 (October), 47-69.
23. Waranis, R.P., Sloan, K.B., 1987. Effects of vehicles and prodrug properties and their interactions on the delivery of 6-mercaptopurine through skin: bisacyloxymethyl-6-mercaptopurine prodrugs. J. Pharm. Sci. 76, 587-595.
24. Yalkowsky, S.H., 1977. Solubility and melting point considerations in drug design. In: Roche, E.B. (Ed.), Design of Biopharmaceutical Properties through Prodrugs and Analogs. American Pharmaceutical Association Academy of Pharmaceutical Sciences, Washington, D.C., pp. 392-408.